trial
as of 2026-07-01Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia
NCTId NCT00833976
at a glance
Phase 4 · Completed
Enrollment 65 (actual)
Sponsored by Massachusetts General Hospital
Primary completion 2013-03
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Completed
Enrollment
65 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2009-07
Primary completion
2013-03
Eligibility
ALL · 18 Years · 75 Years
Interventions & indications
Sponsors
Massachusetts General HospitalLead Sponsor
GlaxoSmithKlineCollaborator
Investigators
1
Marlene P Freeman, MDPrincipal Investigator
Sites
1 total
Boston, United States
Facts & assertions
4 sourced
Enrollment
65
Phase
PHASE4
Primary Completion Date
2013-03
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
collaborator
company
indication
investigator
person